Antiviral drugs for influenza (Formulary)

Important: Formulation and dosage details

Formulation:

Capsules 30mg, 45mg, 75mg

Dosage:

As per SMC 1127/16: Treatment of influenza in children aged <1 year including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms.

Important: Formulation and dosage details

Formulation:

Oral suspension 30mg/5mL

Dosage:

As per SMC 1127/16: Treatment of influenza in children aged <1 year including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms.

Important: Formulation and dosage details

Formulation:

Dry powder for inhalation 5mg/dose

Important: Formulation and dosage details

Formulation:

Injection, solution for infusion 10mg/ml (s)

Dosage:

As per SMC 2204: Treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥ 6 months) when:

• the patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or
• other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.